Pfizer: light on patent filings and heavy on abandonments
An IP purge between 2011 and 2015 saw the lapse of many of the rights the pharma giant developed itself, as well as a number of those it had acquired
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.